HRSA 340B Rebate Pilot — Both Comment Windows Closed; AHA, ASHP, NACHC, WHA All Filed Formal Opposition

Both HRSA 340B Rebate Model comment windows are now closed: the main RFI deadline (April 20) and the burden-focused ICR deadline (April 27). AHA, ASHP, NACHC, and WHA all filed formal opposition arguing the rebate model — converting upfront 340B discounts into back-end rebates — would cost FQHCs and hospitals over $1B/year, jeopardize access, and force compliance burden benefiting Second Sight Solutions (the third-party vendor) and drug manufacturers. Pilot would cover up to 25 drugs from 13 manufacturers with Medicare Drug Price Negotiation Program agreements. Decision now rests with HHS following the Maine District Court vacating the original notice in February 2026. Industry-wide opposition is the strongest unified safety-net front in 340B's 30-year history.